Romagnani S
Excellence Center for Research, Transfer and High Education DENOthe, University of Florence, Firenze, Italy.
Allergy. 2006 Jan;61(1):3-14. doi: 10.1111/j.1398-9995.2006.01005.x.
Several recent data suggest the importance of different types of cells in the regulation of T-cell effector-mediated immune responses. However, a unique specific marker for these cells has not yet been identified. Moreover, in addition to a dedicated functional lineage, even a 'plastic' phenotype of regulatory T cells seems to exist. The lack of a unique specific marker for regulatory T cells, as well as their heterogeneity, make it difficult to determine whether a defect of regulatory T cells plays a role in the pathogenesis of common allergic disorders. Novel therapeutic strategies based on the induction or potentiation of regulatory T cells able to hamper allergic inflammatory reactions are desirable, but their possible efficacy and safety are not yet known. At present, therapeutic strategies able to induce an immune deviation of allergen-specific type 2 T-helper responses to a less polarized phenotype rather than a general immune suppression appear more realistic.
最近的一些数据表明不同类型的细胞在调节T细胞效应器介导的免疫反应中具有重要性。然而，尚未鉴定出这些细胞的独特特异性标志物。此外，除了专门的功能谱系外，调节性T细胞似乎还存在“可塑性”表型。调节性T细胞缺乏独特的特异性标志物及其异质性，使得难以确定调节性T细胞缺陷是否在常见过敏性疾病的发病机制中起作用。基于诱导或增强能够阻碍过敏性炎症反应的调节性T细胞的新型治疗策略是可取的，但其可能的疗效和安全性尚不清楚。目前，能够诱导过敏原特异性2型辅助性T细胞反应向极化程度较低的表型发生免疫偏离而非进行一般免疫抑制的治疗策略似乎更为现实。
